Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with Factor IX-fusion protein or N9-GP extended half-life Factor IX concentrates
Journal of Thrombosis and Haemostasis · 2026-11 · 24 (11) · 3865-3873
DOI: 10.1016/j.jtha.2026.08.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-11. Verfasst von Davide Matino und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McMaster University and the Thrombosis and Atherosclerosis Research Institute (TaARI), Hamilton, Ontario, Canada; Hamilton He…. Hauptthemen laut MEDLINE: Hemophilia B, Factor IX, Recombinant Fusion Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Factor IX (FIX) exhibits significant extravascular distribution and binds type IV collagen in the subendothelial extracellular matrix in the extravascular space, which influences its function and pharmacokinetics (PK). Many hemophilia B patients carry missense F9 mutations that produce circulating, dysfunctional FIX protein [cross-reacting material; (CRM)]. In murine hemophilia models, the presence (CRM+) or absence (CRM-) of dysfunctional FIX modifies the PK and hemostatic efficacy of exogenous FIX. We hypothesized that the PK parameters of extended half-life (EHL) FIX products that have a significant (Fc-FIX) or negligible extravascular distribution might be differently influenced by the presence of endogenous FIX antigen in the vascular and extravascular space. AIM: To investigate the association of F9 variants and the individual PK profile of patients treated with EHL FIX concentrates. METHODS: Individual PK profiles were extracted from the WAPPS-Hemo database, and causal F9 mutations were sourced from linked databases. Differences in PK parameters between CRM+ and CRM- groups were analyzed. RESULTS: Seventy individuals treated with EHL FIX, with known PK profile and gene mutation were included. Among rFIX-Fc recipients, CRM+ patients had significantly lower clearance, longer terminal half-life, higher in vivo recovery, and smaller volume of distribution. No significant PK differences were found between CRM+ and CRM- patients receiving N9-GP. CONCLUSIONS: The pharmacokinetics of EHL FIX products are influenced by their ability to access the extravascular space. For products with substantial extravascular distribution, patient CRM status further modulates PK behavior.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, McMaster University and the Thrombosis and Atherosclerosis Research Institute (TaARI), Hamilton, Ontario, Canada; Hamilton Health Sciences Hemophilia Clinic, Hamilton, Ontario, Canada. Electronic…
- Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, Ontario, Canada.
- Division of Hematology, Children's Hospital of Philadelphia; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Division of Hematology, Department of Pediatrics, Children's H…
- School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada.
- Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy.
- Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Zitieren
APA
Matino, D., Al-Housni, Z., Samelson-Jones, B., Chelle, P., Castaman, G., Teitel, J., Jackson, S., Lillicrap, D., Keepanasseril, A., Chan, A., Lee, K., Edginton, A., & Iorio, A. (2026). Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with Factor IX-fusion protein or N9-GP extended half-life Factor IX concentrates. Journal of Thrombosis and Haemostasis, 24(11), 3865-3873. https://doi.org/10.1016/j.jtha.2026.08.010
Vancouver
Matino D, Al-Housni Z, Samelson-Jones B, Chelle P, Castaman G, Teitel J, et al. Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with Factor IX-fusion protein or N9-GP extended half-life Factor IX concentrates. Journal of Thrombosis and Haemostasis. 2026;24(11):3865-3873. doi:10.1016/j.jtha.2026.08.010
BibTeX
@article{Matino2026,
author = {Matino, Davide and Al-Housni, Zainab and Samelson-Jones, Benjamin and Chelle, Pierre and Castaman, Giancarlo and Teitel, Jerome and Jackson, Shannon and Lillicrap, David and Keepanasseril, Arun and Chan, Anthony and Lee, Kyumin and Edginton, Andrea and Iorio, Alfonso},
title = {Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with Factor IX-fusion protein or N9-GP extended half-life Factor IX concentrates},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {11},
pages = {3865--3873},
doi = {10.1016/j.jtha.2026.08.010}
}
EUVIMED